表柔比星联合紫杉醇脂质体的新辅助化疗方法治疗三阴性乳腺癌的效果

Abstract
Figure/Table
References (16)
Related Citation (15)

Download: PDF (0 KB) HTML (45 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical efficacy of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer (TNBC).Methods80 patients with TNBC in our hospital from June 2015 to June 2016 were selected and randomly divided into the observation group and the control group,40 cases in each group.The control group was given simple neoadjuvant chemotherapy of Epirubicin. The observation group was given neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel.The tumor diameter,breast cancer susceptibility gene(BRCA1)level,fork-box protein A1(FOXA1)level before and after treatment and clinical efficacy,the incidence rate of adverse reaction were compared between the two groups.ResultsThe total effective rate of the observation group was 82.50%,which was higher than 70.00%of the control group,with significant difference (P＜0.05).There was no significant difference in the incidence rate of adverse reaction between the two groups(P＞0.05).The tumor diameter,the level of BRCA1 and FOXA1 after treatment in the two group was lower than that before treatment,with significant difference (P＜0.05).The tumor diameter,the level of BRCA1 and FOXA1 after treatment in the observation group was better than that in the control group,with significant difference(P＜0.05).ConclusionThe neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of TNBC is safe and reliable,with no increase of adverse reaction,and the patients have a higher degree of tolerance while being treated.It is highly significant in clinical application.

Key words： Triple negative breast cancer Epirubicin Lipid Paclitaxel Neoadjuvant chemotherapy Clinical efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WEI Wen-song

Cite this article:

WEI Wen-song. Effects of the neoadjuvant chemotherapy of the combination application of Epirubicin and Lipid Paclitaxel in the treatment of triple negative breast cancer[J]. 中国当代医药, 2016, 23(35): 65-68.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2016/V23/I35/65

[12]	李俏，徐兵河，李青，等.顺铂联合卡培他滨治疗蒽环和紫杉类耐药晚期三阴性乳腺癌的近期疗效与安全性[J].中华肿瘤杂志，2015，37（12）：938-941.
[1]	阮寒光，熊娟，邬蒙，等.TAC与TP方案治疗三阴性乳腺癌的临床观察[J].临床肿瘤学杂志，2013，18（2）：133-136.
[2]	边志杰，杨彬.紫杉醇脂质体联合表柔比星新辅助化疗三阴性乳腺癌临床疗效分析[J].中国现代普通外科进展，2016，19（2）：104-108.
[3]	郝静，赵鹏飞.回顾性分析紫杉醇联合表柔比星新辅助化疗方案治疗三阴性乳腺癌的疗效[J].中国临床药理学杂志，2013，29（7）：496-497，500.
[4]	尼杰，智英辉，只向成，等.P53在三阴性乳腺癌中的表达及其与铂类化疗药物敏感性的关系[J].天津医药，2013，41（4）：317-320.
[5]	袁芃，徐兵河，王佳玉，等.多西他赛联合卡铂方案与表柔比星联合环磷酰胺序贯多西他赛方案辅助治疗三阴性乳腺癌Ⅲ期临床研究的安全性[J].中华肿瘤杂志，2012，34（6）：465-468.
[6]	吕刚，施开德，朱际飚，等.79例三阴乳腺癌临床特点回顾性分析[J].中国医药导报，2015，12（6）：35-39.
[7]	邹伟，朱淑玲，蔡方.雄激素受体、磷酸化蛋白激酶B在三阴性乳腺癌中的表达及意义[J].中国医药导报，2016，13 （8）：124-127.
[8]	王燕.p53对三阴性乳腺癌预后的意义及与铂类化疗药物敏感性的关系[J].中国老年学杂志，2014，34（7）：1804-1805.
[9]	陈宏亮，丁昂，王富文，等.三阴性乳腺癌TAC方案治疗及预后分析[J].复旦学报（医学版），2014，41（6）：765-770，778.
[10]	吴恢升，何劲松，陈伟财，等.TAC新辅助化疗方案治疗三阴性乳腺癌的疗效及预后[J].岭南现代临床外科，2012，12（3）：187-189.
[11]	马文玥，张频，张柏林，等.卡铂联合紫杉醇治疗局部晚期三阴性乳腺癌的Ⅱ期临床研究[J].中华肿瘤杂志，2012，34（10）：770-774.
[13]	林智蔚，苏静.三阴性乳腺癌应用TAC方案术前化疗的临床疗效观察[J].肿瘤基础与临床，2016，29（2）：154-156.
[14]	王丽娜，张崇建，李连方，等.三阴性乳腺癌表柔比星和环磷酰胺联合紫杉醇周疗新辅助化疗临床观察[J].中华肿瘤防治杂志，2015，22（3）：211-215.
[15]	李义慧，王晓红，李玉凤，等.新辅助化疗方案治疗三阴性乳腺癌的效果及生存观察[J].肿瘤研究与临床，2014，26（4）：223-225，234.
[16]	叶国麟，杨劼，古卫权，等.Ki-67表达对“三阴性”乳腺癌新辅助化疗疗效影响[J].河北医学，2013，19（6）：832-834.